Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
BIOA
BIOA
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BIOA News
BioArctic to Release Q4 2025 Report on February 18, 2026
5d ago
Newsfilter
Leqembi Receives Priority Review in China
Feb 09 2026
PRnewswire
Leqembi Receives Priority Review in China
Feb 09 2026
PRnewswire
Leqembi Receives Priority Review in China
Feb 09 2026
Newsfilter
BioArctic's Leqembi Sales Surge in Q4 2025
Feb 06 2026
Newsfilter
BioArctic and Eisai Submit New Drug Application for Lecanemab
Jan 26 2026
Newsfilter
BioAge Labs (BIOA) Prices Upsized Public Offering at $19.50, Targeting $115M
Jan 22 2026
seekingalpha
BioAge Labs Prices Upsized Offering of 5.9 Million Shares at $19.50, Raising $115 Million
Jan 22 2026
Newsfilter
Netflix Reports Q4 Results, Q1 Guidance Misses Estimates
Jan 21 2026
Benzinga
BioAge Labs (BIOA) Proposes $75 Million Public Offering, Expands BGE-102 into Ophthalmology
Jan 21 2026
NASDAQ.COM
BioAge Labs (BIOA) Proposes $75M Public Offering of Common Stock
Jan 20 2026
seekingalpha
BioAge Launches BGE-102 Targeting Diabetic Macular Edema with Promising Clinical Data
Jan 20 2026
Newsfilter
Penguin Solutions Reports Q1 Earnings of $0.49, Shares Up 5.3%
Jan 07 2026
Benzinga
BioArctic and Eisai's Leqembi BLA Accepted in China for Subcutaneous Use
Jan 06 2026
Newsfilter
BioArctic and Eisai's Leqembi Injection Application Accepted in China
Jan 06 2026
PRnewswire
Sanofi Acquires Dynavax for $15.50 per Share, Totaling $2.2 Billion
Dec 24 2025
Benzinga
Show More News
